annb0t
Top 20
Immutep Limited
SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 7116547) entitled âCombined Preparations for the Treatment of Cancer or Infectionâ by the Japanese Patent Office.
This new Japanese patent follows the grant of t...
>>> Read more: Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 7116547) entitled âCombined Preparations for the Treatment of Cancer or Infectionâ by the Japanese Patent Office.
This new Japanese patent follows the grant of t...
>>> Read more: Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
